May 27th 2024
A phase 2b dose-finding study suggests use of clazakizumab was associated with a reduction in hs-CRP among patients undergoing maintenance dialysis.
SGLT2 Inhibitors Benefit CV Outcomes Across Heart Failure, T2D, CKD Populations
June 21st 2023A meta-analysis of 13 trials suggests SGLT2 inhibitors reduced heart failure events and cardiovascular death across these patient populations, with consistent effects in patients with varying disease combinations.
10 Years of SGLT2 Inhibitors: A Decade of Redefining Cardiometabolic Care
March 29th 2023This feature articles commemorates the 10-year anniversary of the FDA's first approval of an SGLT2 inhibitor on March 29, 2013 and provides a snapshot at the class's ascent into the treatment algorithms and guidelines for type 2 diabetes, heart failure, and chronic kidney disease.
Daprodustat Receives FDA Approval for Anemia Caused by CKD on Dialysis
February 1st 2023Announced on February 1, the US Food and Drug Administration's approval of daprodustat (Jesduvroq) represents their first approval of an oral agent for the treatment of anemia caused by chronic kidney disease in people on dialysis.
Study Estimates Event-Free Survival with Combination SGLT2 and ACE/ARBs in People without Diabetes
November 23rd 2022Using data from a trio of trials, investigators provide insight into the potential benefits of combination therapy with SGLT2 inhibitors and RAAS inhibition on event-free survival among patients with chronic kidney disease without diabetes.
Finerenone Reduces Negative CV Outcomes in Type 2 Diabetes, Irrespective of Baseline Kidney Function
October 25th 2022An analysis of data from the FIDELITY program suggests use of finerenone reduced negative heart failure outcomes in people with diabetes and chronic kidney disease, regardless of baseline kidney function.